Depletion of the gut microbiota by antibiotics leads to accelerated immunosuppression during sepsis, caused by decreased release of microorganism associated molecular patterns (MAMPs) and other microbiota derived products into the circulation and…
ID
Bron
Verkorte titel
Aandoening
sepsis, gut flora depletion, systemic immune response
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Side effects, laboratory measurements, functional assays and microbiota composition.
<br><br>
1. Side effects will be registered using a graded scale;<br>
2. A HITchip (16S rRNA) analysis to determine microbiome composition;<br>
3. Laboratory measurements: include inflammatory markers, neutrophil activation and -degranulation;<br>
4. Functional assays: ex vivo stimulation of blood cells with nosocomial pathogens.
Achtergrond van het onderzoek
Objective:
To investigate the role of the gut microbiota in the systemic priming of immune effector cells.
Study design:
Within-subject-controlled intervention study in human volunteers.
Study population:
Twelve healthy male subjects, 18-35 years of age.
Intervention:
All subjects will be treated with broad spectrum antibiotics (ciprofloxacin, vancomycin, metronidazole) for seven days, in order to deplete the gut microbiota. Blood and faeces will be sampled before, 24 hours and 6 weeks after the 7-day period of antibiotics.
Main study endpoints:
Laboratory parameters for inflammatory responses, functional assays (ex vivo stimulation assay) and gut microbiota composition.
Doel van het onderzoek
Depletion of the gut microbiota by antibiotics leads to accelerated immunosuppression during sepsis, caused by decreased release of microorganism associated molecular patterns (MAMPs) and other microbiota derived products into the circulation and diminished priming of bone marrow neutrophils.
Onderzoeksopzet
T=0, day 8, week 7.
Onderzoeksproduct en/of interventie
All volunteers will self-administer the following antibiotics for 7 consecutive days (concomitantly):
1. Vancomycin 250mg 3dd2;
2. Ciprofloxacin 500mg 2dd1;
3. Metronidazol 500mg 3dd1.
Algemeen / deelnemers
Academic Medical Center<br>
University of Amsterdam<br>
Meibergdreef 9
J.M. Lankelma
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5665247
Wetenschappers
Academic Medical Center<br>
University of Amsterdam<br>
Meibergdreef 9
J.M. Lankelma
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5665247
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Healthy;
2. Male between 18 and 35 years of age;
3. Capable of giving written informed consent and able to comply with the requirements
and restrictions;
4. Chemistry panel without any clinically relevant abnormality;
5. Normal defecation pattern (defined as <3x/ day and >3x/week).
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Major illness in the past 3 months or significant chronic medical illness;
2. History of any type of malignancy;
3. Past or current gastrointestinal disease which may influence the gut microbiota;
4. Known positive test for hepatitis C antibody, hepatitis B surface antigen or HIV;
5. Current or chronic history of liver disease, or known hepatic or biliary abnormalities;
6. Use of tobacco products;
7. History, within 3 years, of drug abuse;
8. History of alcoholism and/or drinking more than 3 units of alcohol per day;
9. The subject has received an investigational product within three months of day 1;
10. Use of prescription or non-prescription drugs and herbal and dietary supplements within 6 months;
11. Recent (< 12 months) use of antibiotics (any kind, except for dermal antibiotics);
12. Allergy to antibiotics (any kind);
13. Difficulty swallowing pills;
14. Any other relevant issue.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL3336 |
| NTR-old | NTR3629 |
| CCMO | NL42072.018.12 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
| OMON | NL-OMON36859 |